PARP inhibitors in ovarian cancer treatment

New England Journal of Medicine

Volumn 375, Issue 22, 2016, Pages 2197-2198

  Spriggs, David R ^a   Longo, Dan L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; EDITORIAL; FEMALE; GENE MUTATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR SUPPRESSOR GENE; OVARIAN NEOPLASMS;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84999015248     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1612843     Document Type: Editorial

References (5)

1. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 2003;31:5526-33.
2. Bryant HE, Petermann E, Schultz N, et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 2009;28:2601-15.
3. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11.
4. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154-64.
5. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.